Study #2024-1352
A phase 1b study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of subcutaneous Tarlatamab in subjects with extensive stage small cell lung cancer (DeLLphi 308)
MD Anderson Study Status
Enrolling
Treatment Agent
Tarlatamab
Description
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Extensive Stage Small Cell Lung Cancer
Study phase:
Phase I
Physician name:
Bingnan Zhang
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-211-1427
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.